These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. Grimm CF; Blum HE; Geissler M Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020 [No Abstract] [Full Text] [Related]
3. Economics and the new generation of targeted therapies for non-small cell lung cancer. Ramsey SD J Natl Cancer Inst; 2010 Mar; 102(5):287-8. PubMed ID: 20160167 [No Abstract] [Full Text] [Related]
4. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Scott EN; Meinhardt G; Jacques C; Laurent D; Thomas AL Expert Opin Investig Drugs; 2007 Mar; 16(3):367-79. PubMed ID: 17302531 [TBL] [Abstract][Full Text] [Related]
5. The rational basis of using novel targeted biological agents in non-small cell lung cancer. Ciardiello F Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813 [No Abstract] [Full Text] [Related]
6. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. Friedrich MJ J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503 [No Abstract] [Full Text] [Related]
8. [Protein tyrosine kinase inhibitors in cancer therapy]. Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095 [TBL] [Abstract][Full Text] [Related]
9. [About new treatments in thoracic oncology]. Couraud S Rev Pneumol Clin; 2013 Apr; 69(2):63-4. PubMed ID: 23434002 [No Abstract] [Full Text] [Related]
10. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
11. [Molecular targets in colon cancer]. Borner MM Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454 [TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Gollob JA; Wilhelm S; Carter C; Kelley SL Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795 [TBL] [Abstract][Full Text] [Related]